HTB South


Volume 6 Number 4 October/December 2013

CROI website still blocked

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013, Denver

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Good safety profile with long-acting integrase inhibitor GSK744

TAF comparable to TDF in once-daily pill for ART-naive: 48-week results

Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

High prices for antiretrovirals in middle-income countries outside Africa

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US

NHS England approves four-in-one Stribild (Quad) for limited use

Dolutegravir approved in the US

ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK

From sky high to CHAI* – what needs to be done about dolutegravir pricing?

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

UK pledges £1 billion for Global Fund

UNAIDS reports new HIV infections are reduced by one-third compared to 2001

Southern African treatment guidelines retain CD4 threshold of 350 for starting ART

Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

Activists call EU failure to approve delaminid for MDR tuberculosis due to limited data both “myopic and disappointing”

Circulating memory T follicular helper cells correlate with the development of broadly neutralising antibody responses against HIV

France pledges $1.4 billion for Global Fund

HIV self testing to become legal in the UK from April 2014

Use of ART at baseline by “treatment naïve” patients in HPTN-052

Agreement to develop long-acting rilpivirine as PrEP

UK to lift ban on HIV positive health workers who are on ART with undetectable viral load

CID supplement on HCV and injecting drug users: free online issue

Volume 6 Number 4 October/December 2013 PDF

Volume 6 Number 3 July/September 2013 PDF

Volume 6 Number 3 July/September 2013

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

WHO 2013 guidelines: what about the missing formulations?

WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500

Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013

Non-standard combinations: NRTI-sparing combinations

ARVs and bone health: the role of NRTIs in second-line therapy

No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors

HIV cure research: further capsules at IAS 2013

Partner-dependent immune differences may protect against HIV infection

5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur

Vertical transmission continues to decline in UK and Ireland

Decline in late preterm delivery with vaginal birth in Europe

High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

Decreased growth in ART exposed uninfected infants in Botswana

Antiretrovirals, doses and formulations for children

International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

Dolutegravir approved in the US

Ending global use of d4T: UNITAID to tip market to safer alternatives

TRIPS extension for least developed countries

Community request Gilead to study and develop separate formulation of new tenofovir prodrug

Sad news regarding attempt to duplicate the cure achieved in Timothy Brown

ART reduces HIV reservoirs in elite controllers: implications for cure research

Bangkok Tenofovir Study: US CDC recommends oral PrEP for injection drug users

CROI website: vital community and research resource vanishes

FDA guidance for industry HIV development and trials

Immune system, HIV, and ageing

Post navigation